India's drug regulator panel eases use condition for home-grown vaccine
Coronavirus chronicle
11 March, 2021, 02:45 pm
Last modified: 11 March, 2021, 02:51 pm
Bharat Biotech’s vaccine showed an 81% efficacy in preventing symptomatic Covid-19 in an interim analysis of a late-stage trial in India
Indian Health Minister Harsh Vardhan holds a dose of Bharat Biotech's COVID-19 vaccine called Covaxin, during a vaccination campaign at All India Institute of Medical Sciences (AIIMS) hospital in New Delhi, India, January 16, 2021. REUTERS/Adnan Abidi
An expert panel of India's drug regulator has recommended relaxing norms for the use of a government-backed coronavirus vaccine after it was found to be highly effective in a late-stage trial, the regulator said on its website on Thursday.
"After detailed deliberation, the committee recommended for omission of the condition of the use of the vaccine in clinical trial mode," the Central Drugs Standard Control Organization said.
"However, the vaccine should be continued to be used under restricted use in emergency situation condition."
Bharat Biotech's vaccine showed an 81% efficacy in preventing symptomatic Covid-19 in an interim analysis of a late-stage trial in India, it said last week.
Comments
While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.